Brian Daniel Webster - 17 Jul 2025 Form 4 Insider Report for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)

Reporting relationship: President and Chief Executive Officer, Director
Issuer ticker: KMTS
Reported as of: 17 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jul 2025, 17:20:31 UTC
Prior SEC filing: 06 Mar 2025
Next SEC filing: 31 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Brian Daniel Webster

Key filing fact

Brian Daniel Webster filed Form 4 for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) on 21 Jul 2025.

Key facts

This page summarizes Brian Daniel Webster's Form 4 filing for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jul 2025, 17:20.

Change

Previous filing in this sequence was filed on 06 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001877188 Primary reporting owner

Webster Brian Daniel

Relationship: President and Chief Executive Officer, Director
Address: C/O KESTRA MEDICAL TECHNOLOGIES, LTD., 3933 LAKE WASHINGTON BLVD NE, SUITE 200, KIRKLAND
Signature: /s/ Brian Daniel Webster
Signature date: 21 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KMTS transaction

Common Shares

Award

Transaction value: $0
Shares: +88,235
Change %: +29%
Price: $0.000000
Shares after: 397,577
Date: 17 Jul 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KMTS holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,780,000
Date: 17 Jul 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 1,780,000
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest 29,333 on July 17, 2026, 29,333 on July 17, 2027 and 29,334 on July 17, 2028.

Footnote F2

Includes 1,068,000 fully vested options and 712,000 options that will vest as follows: 356,000 of such options will vest on March 6, 2026, and the remaining 356,000 will vest monthly over the following year.

SEC remarks

President and Chief Executive Officer